Camden Capital, LLC Cytokinetics Inc Transaction History
Camden Capital, LLC
- $896 Million
- Q3 2024
A detailed history of Camden Capital, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Camden Capital, LLC holds 5,056 shares of CYTK stock, worth $248,249. This represents 0.03% of its overall portfolio holdings.
Number of Shares
5,056
Previous 5,056
-0.0%
Holding current value
$248,249
Previous $273,000
2.56%
% of portfolio
0.03%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding CYTK
# of Institutions
410Shares Held
125MCall Options Held
4.6MPut Options Held
2.43M-
Black Rock Inc. New York, NY14.7MShares$720 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$577 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$476 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$382 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$317 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.62B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...